No Data
No Data
Stoke Therapeutics' Zorevunersen Gets FDA Breakthrough Therapy Status in Dravet Syndrome
Pure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On Wednesday
Stoke Therapeutics Shares Rise Premarket on Key FDA Designation
Express News | Stoke Therapeutics Inc - Phase 3 Registration Study Update Expected by Year-End
Express News | Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome
Insider Sale: CHIEF MEDICAL OFFICER of $STOK (STOK) Sells 10,000 Shares